NO983724L - 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase - Google Patents

17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase

Info

Publication number: NO983724L
Authority: NO; Norway
Prior art keywords: compounds; reductase; androgen; mediated; aza
Prior art date: 1996-02-14

Application number

NO983724A

Other languages

English (en)

Norwegian (no)

Other versions

NO983724D0 (no

Inventor

James R Pribish

Cynthia A Gates

Philip M Weintraub

Original Assignee

Hoechst Marion Roussel Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-14

Filing date

1998-08-13

Publication date

1998-10-13

1998-08-13 Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc

1998-08-13 Publication of NO983724D0 publication Critical patent/NO983724D0/no

1998-10-13 Publication of NO983724L publication Critical patent/NO983724L/no

Links

MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 title 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229960003604 testosterone Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
208000035475 disorder Diseases 0.000 abstract 4
230000001404 mediated effect Effects 0.000 abstract 4
239000003098 androgen Substances 0.000 abstract 3
239000000262 estrogen Substances 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
IXELLVJONWOKSN-NQDKFLQJSA-N (1S,3aS,3bS,9aR,9bS,11aS)-1-(cyclopropylamino)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one Chemical compound N([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)N=C4CC3)C)CC[C@@]21C)C1CC1 IXELLVJONWOKSN-NQDKFLQJSA-N 0.000 abstract 1
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
229940123407 Androgen receptor antagonist Drugs 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract 1
208000014311 Cushing syndrome Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
239000003936 androgen receptor antagonist Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
206010020718 hyperplasia Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO983724A 1996-02-14 1998-08-13 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase NO983724L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60127896A	1996-02-14	1996-02-14
PCT/US1997/000469 WO1997030069A1 (en)	1996-02-14	1997-01-09	17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase

Publications (2)

Publication Number	Publication Date
NO983724D0 NO983724D0 (no)	1998-08-13
NO983724L true NO983724L (no)	1998-10-13

Family

ID=24406899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO983724A NO983724L (no)	1996-02-14	1998-08-13	17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase

Country Status (17)

Country	Link
EP (1)	EP0880540B1 (de)
JP (1)	JP2000505444A (de)
KR (1)	KR19990082543A (de)
CN (1)	CN1211256A (de)
AT (1)	ATE219100T1 (de)
AU (1)	AU710208B2 (de)
BR (1)	BR9708301A (de)
CA (1)	CA2244823A1 (de)
DE (1)	DE69713285T2 (de)
DK (1)	DK0880540T3 (de)
ES (1)	ES2178750T3 (de)
HU (1)	HUP9900955A3 (de)
IL (1)	IL125575A0 (de)
NO (1)	NO983724L (de)
NZ (1)	NZ327041A (de)
PT (1)	PT880540E (de)
WO (1)	WO1997030069A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6187925B1 (en) *	1997-12-23	2001-02-13	Merck & Co., Inc.	Intermediates and process for the synthesis of azasteroids
US7005428B1 (en)	1998-06-11	2006-02-28	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en)	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2002046186A1 (en) *	2000-12-08	2002-06-13	Takeda Chemical Industries, Ltd.	Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JP4832303B2 (ja)	2003-05-07	2011-12-07	メルク・シャープ・エンド・ドーム・コーポレイション	アンドロゲン受容体モジュレータおよびこれらの使用
SG185930A1 (en) *	2007-10-29	2012-12-28	Takeda Pharmaceutical	Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
WO2010062506A2 (en) *	2008-10-28	2010-06-03	Lead Therapeutics, Inc.	Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2011088160A2 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
GB201102913D0 (en)	2011-02-18	2011-04-06	Univ Birmingham	Novel therapeutic
CN109438549B (zh) *	2018-12-13	2022-01-04	湖北葛店人福药业有限责任公司	一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264427A (en) *	1992-01-29	1993-11-23	Research Corporation Technologies, Inc.	20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
JPH07506575A (ja) *	1992-05-21	1995-07-20	アンドルシェルシュ・インコーポレイテッド	テストステロン５α−レダクターゼ活性の阻害剤
US5486511A (en) *	1993-05-25	1996-01-23	Merrell Dow Pharmaceuticals Inc.	4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase

1997
- 1997-01-09 ES ES97901995T patent/ES2178750T3/es not_active Expired - Lifetime
- 1997-01-09 CN CN97192283A patent/CN1211256A/zh active Pending
- 1997-01-09 DK DK97901995T patent/DK0880540T3/da active
- 1997-01-09 EP EP97901995A patent/EP0880540B1/de not_active Expired - Lifetime
- 1997-01-09 AU AU15767/97A patent/AU710208B2/en not_active Ceased
- 1997-01-09 KR KR1019980706280A patent/KR19990082543A/ko not_active Ceased
- 1997-01-09 AT AT97901995T patent/ATE219100T1/de not_active IP Right Cessation
- 1997-01-09 NZ NZ327041A patent/NZ327041A/xx unknown
- 1997-01-09 BR BR9708301A patent/BR9708301A/pt not_active IP Right Cessation
- 1997-01-09 HU HU9900955A patent/HUP9900955A3/hu unknown
- 1997-01-09 WO PCT/US1997/000469 patent/WO1997030069A1/en not_active Ceased
- 1997-01-09 DE DE69713285T patent/DE69713285T2/de not_active Expired - Fee Related
- 1997-01-09 IL IL12557597A patent/IL125575A0/xx unknown
- 1997-01-09 PT PT97901995T patent/PT880540E/pt unknown
- 1997-01-09 CA CA002244823A patent/CA2244823A1/en not_active Abandoned
- 1997-01-09 JP JP9529338A patent/JP2000505444A/ja active Pending
1998
- 1998-08-13 NO NO983724A patent/NO983724L/no unknown

Also Published As

Publication number	Publication date
AU710208B2 (en)	1999-09-16
AU1576797A (en)	1997-09-02
DK0880540T3 (da)	2002-10-07
CN1211256A (zh)	1999-03-17
EP0880540A1 (de)	1998-12-02
IL125575A0 (en)	1999-03-12
ES2178750T3 (es)	2003-01-01
PT880540E (pt)	2002-10-31
WO1997030069A1 (en)	1997-08-21
ATE219100T1 (de)	2002-06-15
DE69713285D1 (en)	2002-07-18
KR19990082543A (ko)	1999-11-25
BR9708301A (pt)	1999-08-03
HUP9900955A3 (en)	2000-06-28
DE69713285T2 (de)	2003-01-02
NO983724D0 (no)	1998-08-13
HUP9900955A2 (hu)	1999-07-28
CA2244823A1 (en)	1997-08-21
JP2000505444A (ja)	2000-05-09
NZ327041A (en)	1999-11-29
EP0880540B1 (de)	2002-06-12

Similar Documents

Publication	Publication Date	Title
CA2050291A1 (en)	1990-09-11	Combination therapy for the treatment of estrogen sensitive diseases
DK1556058T3 (da)	2008-03-03	Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
IL260127B (en)	2022-04-01	mek inhibitors and methods of using them
SG141468A1 (en)	2008-04-28	Novel curcumin analogues and uses thereof
NO20043531L (no)	2004-10-25	Indazolforbindelser som er nyttige som proteinkinaseinhibitorer
BRPI0412439A (pt)	2006-09-05	compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições
ATE466832T1 (de)	2010-05-15	Neue curcuminanaloga und deren anwendungen
HUP0003194A2 (hu)	2001-07-30	Triozin-kináz-gátló alkalmazása prosztatarák kezelésére szolgáló szinergista gyógyszerkészítményben
ATE369755T1 (de)	2007-09-15	Verwendung von diphenylmethan-derivaten als tyrosinase-inhibitoren
BRPI0607523A2 (pt)	2009-09-08	compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
TR200700134T1 (tr)	2007-02-21	Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
NO20062679L (no)	2006-08-10	Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
BR0312845A (pt)	2005-06-07	Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
NO983724D0 (no)	1998-08-13	17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase
AU3029297A (en)	1998-01-05	7alpha-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7alpha-(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE60208694D1 (de)	2006-04-06	Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
UA96277C2 (en)	2011-10-25	Benzimidazole derivatives
IL152097A0 (en)	2003-05-29	Use of pyrazole derivatives for treating infertility
UA85203C2 (en)	2009-01-12	17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
SG149081A1 (en)	2009-01-29	Treatment of aromatase inhibitor therapy-related osteoporosis
PL370361A1 (en)	2005-05-16	Alkyl urea retinoid agonists i
NO952601L (no)	1996-01-02	Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
NO20045343L (no)	2004-12-06	Ny kombinasjon for behandling av luftveisforstyrrelser
EA200300061A1 (ru)	2003-04-24	Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и алкилирующих агентов
DE69912477D1 (de)	2003-12-04	Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs